Sanofi SA

SNY

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

10 best US blue-chip stocks to buy for the long term

The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance

Can you achieve global diversification with multinational companies?

A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,456.2090.501.08%
CAC 407,707.17113.301.49%
DAX 4022,853.92356.941.59%
Dow JONES (US)40,752.9683.600.21%
FTSE 1008,554.7057.900.68%
HKSE22,504.68385.271.74%
NASDAQ17,710.74264.401.52%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,327.89179.291.48%
S&P 5005,604.1435.080.63%
S&P/ASX 2008,238.0092.401.13%
SSE Composite Index3,279.037.62-0.23%

Market Movers